Your Article Summary
See Latest ArticlesOff-label indications for imiquimod
Dermatology Online Journal, 06/25/09
Ganjian S et al. - Imiquimod has rapidly been recognized as a potential candidate for off-label use. Although the FDA has approved imiquimod only for the treatment of external genital and perianal warts, actinic keratoses, and superficial basal cell carcinoma, successful clinical studies teach the greater potential and efficacy of imiquimod in treating more cutaneous viral lesions.
Related Articles
Enlarging purple pruritic nodules on the dorsal neck
The Clinical Advisor, 11/05/09
Relevance Score: 77%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Muscle Weakness After Repeated Injection of Botulinum Toxin Type A Evaluated According to Bite Force Measurement of Human Masseter Muscle
Dermatologic Surgery, 12/10/09
Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
Dermatologic Surgery, 12/10/09
A case of atopic dermatitis-associated lichen amyloidosis successfully treated with oral cyclosporine and narrow band UVB therapy in succession
Journal of Dermatological Treatment , 12/10/09
Today in Dermatologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Basic fibroblast growth factor stimulates the proliferation of human dermal fibroblasts via the ERK1/2 and JNK pathways
British Journal of Dermatology, 12/10/09
New insights into pigmentary pathways and skin cancer
British Journal of Dermatology, 12/10/09
Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients
Annals of Surgical Oncology, 12/10/09
Today in Dermatopathology...keeping you current
Receive free subspecialty "5-minute updates" via email
Idiopathic Chilblains
American Journal of Medicine, 12/10/09
Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
Dermatologic Surgery, 12/10/09
Basic fibroblast growth factor stimulates the proliferation of human dermal fibroblasts via the ERK1/2 and JNK pathways
British Journal of Dermatology, 12/10/09